Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
Date:2/21/2013

THE WOODLANDS, Texas, Feb. 21, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2012.

"We continued to make significant progress in the development of our pipeline in 2012, highlighted by positive results from clinical studies of LX4211 in diabetes and telotristat etiprate in carcinoid syndrome," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon. "We are pleased to have commenced the Phase 3 program for telotristat etiprate in carcinoid syndrome, and continue to progress in our preparations for LX4211 Phase 3 initiation. We also look forward to significant proof-of-concept results in irritable bowel syndrome (IBS) with LX1033, ulcerative colitis with telotristat etiprate, and type 1 diabetes with LX4211 in 2013."

Key Developments in 2012

  • LX4211:  Lexicon reported positive results from a 12-week Phase 2b clinical trial of LX4211, a dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1 and SGLT2) in patients with type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy. LX4211 treatment produced substantial, dose-dependent and statistically-significant reductions in hemoglobin A1c (HbA1c), with patients in the high dose (400 mg QD) LX4211 treatment arm having a mean HbA1C reduction from baseline of 0.95 percent (p<0.001). In patients randomized to placebo, HbA1C decreased by 0.09 percent. LX4211 treatment also produced significant reduct
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Lexicon To Present At The BIO CEO & Investor Conference
    2. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
    3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
    4. Lexicon to Provide Third Quarter 2012 Financial Results
    5. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
    6. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
    7. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
    8. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
    9. Lexicon to Provide Second Quarter 2012 Financial Results
    10. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
    11. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/20/2014)... 20, 2014  ResMed (NYSE: RMD ... Data Exchange program, a comprehensive suite of software ... and other health care providers. ... critical patient information. It integrates valuable sleep and ... patient management platforms with customers, in-house or third-party ...
    (Date:10/20/2014)... --  BioNano Genomics announced today achievement of a major ... data at 30X depth, sufficient for a genome map, in ... established and demonstrated for the IrysChip TM V2, the ... and will be rolled out to BioNano,s collaborators and customers ... advancement at the American Society for Human Genetics (ASHG) ...
    (Date:10/20/2014)... 2014   Taiho Oncology, Inc. , a ... Japan ), announced that the U.S. Food ... for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), ... the treatment of refractory metastatic colorectal cancer (mCRC), ... NDA submission to the FDA. According to the ...
    Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
    ... for the most common, pathogens, including ... Oct. 26 Arpida (SWX:,ARPN) today presented ... III,clinical trials at the 48th Interscience Conference ... of America (IDSA) 46th,annual meeting in Washington, ...
    ... 26 Sequoia Pharmaceuticals presented,positive results today from ... inhibitor (PI). One study based on an in ... SPI-256 with HIV protease,provides a rationale for its ... second study conducted in healthy volunteers demonstrates,that SPI-256 ...
    Cached Medicine Technology:Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor 2Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor 3Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor 4
    (Date:10/22/2014)... Amy Norton HealthDay Reporter ... remain riveted on the three Ebola cases in Dallas. But, ... health threat to Americans. President Barack Obama on Friday ... the virus, which has infected two Dallas nurses who cared ... at Texas Health Presbyterian Hospital. But the U.S. cases ...
    (Date:10/22/2014)... (PRWEB) October 22, 2014 Hay House is ... Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written by ... Yoga & Recovery. This book is meant to help ... a life of recovery. , Recovery 2.0 is not ... Steps; Recovery 2.0 is a guide for what comes next. ...
    (Date:10/22/2014)... 2014 Healthcare professionals who are ... education at home or on-the-go via laptops, tablets ... brand new, premium Seminar-on-Demand CE courses. The new ... 2,000 hours of CE course offerings, ... experience. With such a diverse library, there’s something ...
    (Date:10/22/2014)... Prussia, PA (PRWEB) October 22, 2014 ... recognized as an industry leader with over 25 years ... winning team leader in the areas related to EDI, ... Mr. Carlson is an Editorial Advisory Board member for ... Council Educator. Blue Fin Group is a management ...
    (Date:10/22/2014)... -- Two sisters in high school have developed ways ... Medha Krishen use electronic stethoscopes, which electronically amplify body ... patterns or heartbeats. Ilina, a senior at Port ... a way to detect early lung damage in people ... Ilina recorded one breath cycle each from 16 smokers, ...
    Breaking Medicine News(10 mins):Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
    ... Surgeon, went ahead and purchased a medical equipment from ... permission// from the hospital authorities. Apparently, he had already ... at James Paget Hospital, Gorleston, Norfolk. A retractor, which ... placed the huge order. ,Since a retractor ...
    ... public demand for transparency in clinical trials involving humans, ... firms to register all such studies and include details ... ,'Registration of all clinical trials and full disclosure ... fundamental to ensuring transparency in medical research and fulfilling ...
    ... sum of Rs 749 crore would be spent in Haryana ... 2010 in order to reduce infant mortality rate// in the ... ,Addressing a Nav Nirman Rally organised by President of All ... here, Hooda said emphasis has been laid on improving health ...
    ... to the recent study it is said that researchers are ... mental illness by DNA profiling//. They are going to develop ... such as schizophrenia and autism. The skin tests are to ... which opened near Inverness. ,By the end of ...
    ... new Health Minister of Northern Ireland, expressing his apology over ... has stated that women who had suffered distress and anxiety ... out the delay in the cancer diagnosis of six women ... increase in risk of dying from breast cancer attributable to ...
    ... the onslaught of Foot-and-mouth disease. The disease has not spared ... only a small portion of the cattle// and pigs are ... and not as dangerous as avian flu," said Vu Ngoc ... in Hanoi. "There have not been a big number of ...
    Cached Medicine News:Health News:Minster Apologizes To Women Involved In Breast Cancer Screening Scandal 2
    Compact tray features all components for urethral catheterization....
    ... For the first time, the ... pre-analytical, analytical, and post-analytical solution coupled ... the five major steps a sample ... communications between each one - it ...
    Convective Air Warming Blankets...
    MAMMOMAT 3000 Nova supports high-volume screening as well as interventional diagnostics. Versatile procedural capabilities include magnification, stereotactic biopsy, needle localization, and specime...
    Medicine Products: